Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
Updated Monday, 2/24.While the calendar looks quiet for the week ahead, some small deals may join late.Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two medical...read more
The 2025 IPO market has kicked off with a steady stream of large deals, and new filing activity signals more to come. Thirteen IPOs planning to raise $100 million or more have joined the pipeline, the most in a single month since January 2022....read more
US IPO Week Ahead: Small IPOs may list amid market volatility
...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
US IPO Week Ahead: IPO market set to end February on a quiet note
Updated Monday, 2/24.While the calendar looks quiet for the week ahead, some small deals may join late.Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two medical...read more
Sizable IPO filings reach a three-year high amid steady stream of deals
The 2025 IPO market has kicked off with a steady stream of large deals, and new filing activity signals more to come. Thirteen IPOs planning to raise $100 million or more have joined the pipeline, the most in a single month since January 2022....read more